Taking nature’s lead
in antimicrobials

NovaBiotics’ novel antimicrobial Luminaderm highly effective against Multi drug resistant MRSA
16/06/2017

NovaBiotics participating in BIO 2017 in San Diego
15/06/2017

NovaBiotics at European Cystic Fibrosis Conference in Seville
06/06/2017

NovaBiotics at American Society for Microbiology
26/05/2017

30 subjects now randomised in Lynovex CARE-CF-1 trial
10/05/2017

NovaBiotics contribution to ECCMID 2017
13/04/2017

NovaBiotics Quality Management System Achieves ISO 9001 certification
11/04/2017

NovaBiotics to host live Twitter Lynovex Q&A
24/03/2017

NovaBiotics Chief Executive Addresses 'Superbugs & Superdrugs' Conference on Antimicrobial Drug Discovery
21/03/2017

NovaBiotics CEO to speak at 19th Superbugs & Superdrugs Conference
17/03/2017

NovaBiotics secures an additional £3.0 million investment from Woodford Investment Management
03/03/2017

NovaBiotics CEO to speak at 10th Berlin Conference on Life Sciences
21/02/2017

NovaBiotics at ECCMID 2017
25/01/2017

NovaBiotics CEO featured as one of 15 women leading in European Biotech
18/01/2017

NovaBiotics announces first patients dosed in Lynovex clinical study
16/01/2017

NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.

The Company’s advanced portfolio of antimicrobial therapeutic candidates targets large and important markets with significant unmet clinical needs, including Lynovex (in oral and inhaled form), an orphan drug candidate for cystic fibrosis (CF), Novexatin, a potential step change therapy for onychomycosis (being co-developed with and out-licensed to Taro Pharmaceuticals) and Novamycin, a novel antifungal peptide in development for the treatment of aspergillosis, candidiasis and cryptococcosis. Novexatin and Novamycin are among the first in class peptide anti-infectives which the company continues to derive from its proprietary antimicrobial peptide rational drug design platform.  Lynovex and Nylexa have been developed as novel antimicrobial adjunct therapies from the company's more recently established aminothiol platform.